Retina Service at the Gavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, CA, USA.
Retina. 2012 Sep;32 Suppl 2:S225-8; discussion S228-31. doi: 10.1097/IAE.0b013e31825bc593.
The vitreous may play an important role in the pathogenesis of various retinal disorders. Pharmacologic vitreolysis uses intravitreal pharmacologic agents to provide liquefaction of the vitreous and complete vitreoretinal separation. Ocriplasmin, a genetically engineered version of plasmin, has been shown in clinical trials to be able to safely release vitreomacular adhesion and close Stage 2 macular holes in a significant number of patients. Advancements in the development of this safe and effective method of vitreolysis have provided an alternative, nonsurgical treatment option to physicians who manage these patients. A roundtable of clinical investigators convened to discuss and summarize recent progress in pharmacologic vitreolysis. Preclinical studies, and efficacy and safety data from controlled clinical trials of ocriplasmin were presented and discussed. Case studies were then presented to provide an opportunity for experts to reveal their specific thoughts regarding ocriplasmin for the treatment of vitreomacular adhesion and resulting vitreomacular traction and macular holes, based on their own interpretation of current clinical data and experience.
玻璃体可能在各种视网膜疾病的发病机制中起重要作用。药理玻璃体溶解术使用眼内药理制剂提供玻璃体液化和完全玻璃体视网膜分离。在临床试验中，已证明基因工程版纤溶酶原 ocriplasmin 能够安全地释放玻璃黄斑粘连，并使大量患者的 2 期黄斑裂孔闭合。这种安全有效的玻璃体溶解方法的发展进步为治疗这些患者的医生提供了一种替代的非手术治疗选择。一个临床研究人员圆桌会议讨论并总结了药理玻璃体溶解的最新进展。介绍和讨论了纤溶酶原 ocriplasmin 的临床前研究和对照临床试验的疗效和安全性数据。然后提出了病例研究，为专家提供了机会，根据他们对当前临床数据和经验的解释，就 ocriplasmin 治疗玻璃黄斑粘连和由此产生的玻璃体黄斑牵引和黄斑裂孔的具体想法进行交流。
